Return to search

Pheast Therapeutics pockets $76m Series A

Pheast Therapeutics, a developer of novel checkpoint therapies to fight cancer, has raised $76 million in Series A funding.

Pheast Therapeutics, a developer of novel checkpoint therapies to fight cancer, has raised $76 million in Series A funding. Catalio Capital Management and ARCH Venture Partners led the round.

Source: Press Release